{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"30.4","value":"11.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"title":"PAN: Cycle 1 Day 1 (C1D1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"41.5","value":"18.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"}],"units":"Participants"}],"title":"PAN: Cycle 1 Day 8 (C1D8)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"42.1","value":"1.06"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"title":"BJB432: C1D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"84.2","value":"4.38"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"}],"units":"Participants"}],"title":"BJB432: C1D8"}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"description":"Cmax: The maximum (peak) observed plasma concentration. PK sample collection was performed in subjects who agreed to blood samplings for the PK assessments of PAN and BTZ. The order of administration of the 3 study treatment components was 1) PAN, 2) Dex, and 3) BTZ.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants were administered LBH589 (panobinostat)in combination with bortezomib and dexamethasone 2 weeks on/1 week off.","id":"OG000","title":"LBH589 + Bortezomib + Dexamethasone"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic Analysis Set (PAS): The PK analysis set for PAN (PAS-PAN) consisted of all subjects with at least one evaluable PK concentration of PAN. The PK analysis set for BTZ (PAS-BTZ) consisted of all subjects with at least one evaluable PK concentration of BTZ.","reportingStatus":"POSTED","timeFrame":"Predose, 0.5h, 1h, 2h, 3h, 4h 8h, 24h, 48h post dose","title":"Composite PharmacoKinetics (PK) of Panobinostat and Bortezomib: Cmax","type":"SECONDARY","unitOfMeasure":"ng/mL"}